多模态技术联合术中唤醒麻醉在Broca区胶质瘤患者语言功能区定位中的作用

目的探讨多模态技术联合术中唤醒麻醉在Broca区胶质瘤患者语言功能区定位中的作用和手术疗效。方法回顾性分析2011年1月至2017年12月复旦大学附属华山医院神经外科行手术切除的Broca区胶质瘤患者的临床资料,共42例。术前采用功能磁共振成像和弥散张量成像技术重建语言皮质激活区域和皮质下传导通路,术中在唤醒麻醉下通过直接电刺激技术定位语言皮质和皮质下传导通路,并在术中磁共振、实时神经影像导航系统引导下行肿瘤切除。根据肿瘤是否侵犯中央前回腹侧部(vPMC)将患者分为未侵犯vPMC(仅侵犯额下回后部)组24例,侵犯vPMC组18例,评估并比较两组患者语言功能区定位情况和疗效。结果42例患者均完成术中语言功能区定位,34例(81.0%)至少有1个阳性定位点;3例(7.1%)在定位过程中出现癫痫局灶性发作。25例患者肿瘤为全切除,17例为非全切除。术后病理学证实世界卫生组织(WHO)肿瘤分级Ⅱ级者23例,Ⅲ级者14例,Ⅳ级者5例。术后1个月内(近期)16例(38.1%)患者有语言功能障碍,其中12例3个月内恢复,4例(9.5%)未恢复。术后所有患者随访6~84个月(中位数为24个月),14例出现肿瘤进展,其中11例死亡。与未侵犯vPMC组比较,侵犯vPMC组肿瘤的WHO级别高(P=0.011),术后近期语言功能障碍的发生比率高[分别为10/18、25.0%(6/24),P=0.044],无进展生存期[分别为(28.4±5.2)个月、(80.7±3.2)个月]和总生存期[分别为(38.8±5.8)个月、(80.8±3.2)个月]均短。差异均有统计学意义(均P<0.001)。结论多模态技术联合术中唤醒麻醉治疗Broca区胶质瘤有助于在最大化切除肿瘤的同时,保护患者的语言功能。其中肿瘤侵犯vPMC比仅侵犯额下回后部者引起近期语言功能障碍率更高,预后更差。     

Wireless body area network for health monitoring

A Wireless Sensor Networks (WSNs) consists basically of a group of nodes, that communicate with each other through a wireless transmission, and does not need any existing infrastructure. The recent developments in technology and wireless communication, to be used in various applications, foster the development of Wireless Body Area Networks (WBANs). They are emerging as important networks in order to reduce the need for patients, and to help the elderly and chronically ill people to live an independent life. In this paper, we propose a routing protocol for wireless body area networks, to transfer data in the network with minimum energy consumption, and longer network lifetime through multi-hop communication. The proposed protocol has been verified by performing simulations, and the obtained results show that our routing protocol ensures a robust optimisation of the energy consumption which helps to increase the lifetime of the network and its stability.     

多层螺旋CT定量评估慢性阻塞性肺疾病病情的价值

目的探讨多层螺旋CT(MSCT)定量评估慢性阻塞性肺疾病病情的价值。方法选取2017年8月～2018年7月在湖州市第一人民医院就诊的73例慢性阻塞性肺疾病(COPD)患者作为研究对象,按照病情轻重分为Ⅰ组(轻度患者17例)、Ⅱ组(中度患者32例)、Ⅲ组(重度患者24例),并选取同期于该院体检的健康者20例为对照组。所有研究对象均行MSCT低剂量扫描,观察比较各组管腔面积(Ai)、支气管壁面积百分比(WA%)、管壁厚度与体表面积比值(T/BSA)、壁厚度与直径比值(TDR),同时予以肺功能检查,采用定量CT气道分析软件分别测量气道相关参数,并用Siemens Pulmo软件Pearson定量分析其相关性。结果对照组、Ⅰ组、Ⅱ组、Ⅲ组的FEV1均呈逐渐下降趋势,FEV1/FVC呈逐渐上升趋势,差异均有统计学意义(P0.05)。对照组、Ⅰ组、Ⅱ组、Ⅲ组的WA%、T/BSA、TDR比较,均呈逐渐上升趋势,Ai呈下降趋势,差异均有统计学意义(P0.05)。FEV1与WA%、TDR之间呈负相关(r=-0.291,P=0.000;r=-0.473,P=0.000),FEV1/FVC与WA%、TDR之间呈正相关(r=0.285,P=0.000;r=0.472,P=0.000)。结论 MSCT扫描及定量分析可为COPD患者气道病变情况提供可靠的评估信息。     

Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction

Dietary supplements and foods can interact with various drugs, leading to possible clinical concerns. This study aimed to investigate the effect of orally administered sinapic acid (SA) on the pharmacokinetics of aripiprazole (APZ) in rats and its possible modulatory effects on hepatic cytochrome P450 (CYP3A2 and CYP2D6) expression in the liver tissues. Single dose and multiple dose parallel groups of wistar rats were categorized into six groups (n = 6 each) which abstained from food for 12 h prior to the experiment, while water was allowed ad libitum. The investigation was carried out for single dose: Group I was treated with normal saline orally for 15 days (normal control). Group II was administered normal saline orally for 15 days and received APZ (3 mg/kg p.o.) on day 15. Group III received SA (20 mg/kg p.o.) for 15 days and received APZ (3 mg/kg p.o.) on day 15. Group IV was treated with SA (20 mg/kg p.o.) for 15 days. For the multiple dose study, Group I was treated with normal saline orally for 15 days (normal control); Group II received APZ (3 mg/kg p.o.) daily for 15 days; Group III was administered with SA (20 mg/kg p.o.) and APZ (3 mg/kg p.o.) for 15 days and Group IV received SA (20 mg/kg p.o.) for 15 days. The group I and IV were kept common in single and multiple dose groups. After last APZ dose, plasma samples were collected and APZ concentrations were determined using an UPLC-MS/MS technique. The pharmacokinetic parameters were calculated using a non-compartmental analysis. The concomitant administration of APZ with SA (as single or multiple dose) resulted in an increase in APZ absorption and a decrease on its systemic clearance. This was associated with a reduction in CYP3A2 and CYP2D6 protein expressions by 33–43% and -71–68% after the single and multiple co-administration, which are two enzymes responsible of the metabolism of APZ. Therefore, a reduction in the metabolic clearance appears to be the mechanism underlying the drug interaction of dietary supplement containing SA with APZ. Therefore, the concomitant administration of SA and APZ should be carefully viewed. Further investigations are required to assess the clinical significance of such observations in humans.     

贵州铜仁地区人体结膜吸吮线虫病1例

本文报道1例贵州省铜仁地区人体结膜吸吮线虫感染病例。     

Pinnacle3 9.10计划系统不同子野面积参数对宫颈癌自动调强放疗计划的影响

目的探讨基于运用Pinnacle^39.10计划系统自动计划模块,在不影响肿瘤靶区剂量分布和危机器官(OAR)受量的前提下,最小子野面积参数对宫颈癌自动调强放疗(AP-IMRT)计划的影响。方法收集2018年9月至2019年6月10例宫颈癌患者进行AP-IMRT计划设计,每例患者设计10个AP-IMRT计划,计划靶区(PTV)处方剂量为50Gy/25f,采用7野均分的固定野照射,最小子野面积分别设置为4 cm^2、9 cm^2、14 cm^2、20 cm^2、25 cm^2、40 cm^2、50 cm^2、60 cm^2、80 cm^2和100 cm^2,最小子野数目为70个,最小子野跳数为7MU。采用直接机器参数优化(DMPO)算法评价靶区及OAR剂量分布。结果随着最小子野面积从4 cm^2增大至100 cm^2,AP-IMRT计划的总机器跳数从(649±32)MU降低至(312±26)MU,总子野数目从(69±1)个降低至(28±3)个,分别降低了53%和48%。AP-IMRT计划PTV的均匀性指数(HI)在子野面积4~100 cm^2的范围内呈递增趋势,最小子野面积60~100 cm^2与最小子野面积为4~50 cm^2的HI相比,差异有统计学意义(P<0.05)。PTV的适形指数(CI)在最小子野面积为4 cm^2、9 cm^2和14 cm^2时差异有统计学意义(P<0.05)。不同最小子野面积的AP-IMRT计划间OAR受照射剂量的差异无统计学意义(P>0.05)。结论在使用Pinnacle^39.10计划系统设计宫颈癌AP-IMRT计划时,最小子野面积参数设置在14~50 cm^2的范围内均可满足临床剂量学要求,同时子野数量和机器跳数显著减少。     

基于不同体位定位CT探讨不同勾画者勾画保乳术后部分乳腺外照射靶区差异

目的 比较基于不同体位定位CT下不同勾画者勾画保乳术后部分乳腺外照射(EB-PBI)靶区差异。方法 2016-2017年间27例保乳术后拟行EB-PBI的患者在自由呼吸状态下序贯完成俯卧位及仰卧位模拟定位3DCT扫描。5位勾画者分别在两种不同体位CT图像上基于术腔金属夹完成瘤床(TB) 靶区勾画和临床靶区(CTV) 的构建。比较两种体位不同勾画者间的靶体积、变异系数(COV)、匹配指数(MD)差异。结果 无论仰卧位还是俯卧位时,不同勾画者所勾画TB、CTV均不同(P<0.001、P=0.001、P<0.001、P=0.001)。俯卧位时不同勾画者CTV交集比仰卧位大5.79cm³(P=0.011)。仰卧位时5位勾画者的COVCTV显著大于俯卧位(P=0.014)。仰卧位时5位勾画者的MDTBTB及MDTBCTV均显著劣于俯卧位(P<0.001、P=0.001)。结论 与仰卧位相比,基于俯卧位构建EB-PBI靶区可显著减少不同勾画者间差异,提高勾画者间的一致性。因此,在自由呼吸状态下基于俯卧位施行EB-PBI更为合理。     

Design,synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy

Angiokinases, such as vascular endothelial-, fibroblast- and platelet-derived growth factor receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti-angiogenesis therapy using multi-angiokinase inhibitor has achieved great success in recent years. In this study, we presented the design, synthesis, target identification, molecular mechanism, pharmacodynamics (PD) and pharmacokinetics (PK) research of a novel triple-angiokinase inhibitor WXFL-152. WXFL-152, identified from a series of 4-oxyquinoline derivatives based on a structure–activity relationship study, inhibited the proliferation of vascular endothelial cells (ECs) and pericytes by blocking the angiokinase signals VEGF/VEGFR2, FGF/FGFRs and PDGF/PDGFRβ simultaneously in vitro. Significant anticancer effects of WXFL-152 were confirmed in multiple preclinical tumor xenograft models, including a patient-derived tumor xenograft (PDX) model. Pharmacokinetic studies of WXFL-152 demonstrated high favourable bioavailability with single-dose and continuous multi-dose by oral administration in rats and beagles. In conclusion, WXFL-152, which is currently in phase Ib clinical trials, is a novel and effective triple-angiokinase inhibitor with clear PD and PK in tumor therapy.